{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:14Z","timestamp":1793330774866,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"\n Importance<\/jats:title>\n There are limited prognostic statistics and data available on survival outcomes for patients with mycosis fungoides (MF) in Asia.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the prognostic factors and survival outcomes of patients with MF among a cohort in China.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a retrospective cohort study of patients with MF who received treatment at a tertiary referral center for skin lymphoma (Peking University First Hospital, Beijing, China) from August 1, 2009, to August 31, 2021. Data were analyzed from September 1, 2021, to December 31, 2022.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS); for prognostic factors, hazard ratios (HRs), and adjusted HRs (aHRs; adjusted for sex, age, and overall TNMB [tumor, node, metastasis, blood] stage) determined using the Cox proportional hazards model.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study cohort comprised 461 patients with MF (median [range] age at diagnosis, 46 [5-87] years; 275 [59.7%] men and 186 [40.3%] women; 461 [100%] Chinese). The overall 5-year rate was 82.2% for OS, 83.5% for DSS, and 79.6% for PFS. Stage-specific 5-year OS rates were 95.7% for stage IA, 93.2% for IB, 95.7% for IIA, 70.1% for IIB, 55.3% for III, and 23.6% for IV. Compared with a UK cohort, our Chinese cohort had a younger median age at diagnosis (46 years vs 54 years) and a more favorable 5-year OS (82.2% vs 75.0%); however, after adjusting for age, the discrepancy in the 5-year OS rate was diminished (77.3% vs 76.4%). Cox models revealed that unfavorable predictors of OS, PFS, and DSS, respectively, were: age older than 60 years (aHR [95% CI], 2.25 [1.28-3.96]; 2.09 [1.16-3.76]; 2.27 [1.39-3.72]); advanced TNMB stage; advanced overall stage; large-cell transformation (aHR [95% CI], 2.16 [1.17-3.99]; 2.29 [1.21-4.33]; 2.21 [1.26-3.86]); and elevated lactate dehydrogenase levels (aHR [95% CI], 3.92 [1.64-9.36]; 4.77 [1.86-12.22]; 5.05 [2.23-11.42]). Biological sex and plaque lesion type were not associated with prognosis among this study cohort.<\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n The findings of this retrospective cohort study of patients with MF in China suggest that Asian patients are diagnosed at a younger age and have a higher 5-year OS compared with patients of other races in studies in other countries (predominantly White). Prognostic factors were similar to those of previous studies, except for patient sex and plaque lesion type.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.2634","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T11:01:02Z","timestamp":1692183662000},"page":"1059","source":"Crossref","is-referenced-by-count":33,"title":["Prognostic Factors and Survival Outcomes Among Patients With Mycosis Fungoides in China"],"prefix":"10.1001","volume":"159","author":[{"given":"Zhuojing","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Lin","sequence":"additional","affiliation":[{"name":"Peking University Clinical Research Institute, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Tsinghua Changgung Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Gao","sequence":"additional","affiliation":[{"name":"Peking University Clinical Research Institute, Peking University, Beijing, China"},{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China"},{"name":"Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China"},{"name":"National Clinical Research Center for Skin and Immune Diseases, Beijing, China"},{"name":"National Medical Products Administration, Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"doi230035r1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"6","key":"doi230035r2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.v66.6","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes.","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"doi230035r3","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1111\/jdv.v34.10","article-title":"Mycosis fungoides: developments in incidence, treatment and survival.","volume":"34","author":"Kaufman","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"doi230035r4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous t-cell lymphoma in the US from 2000 to 2018: a SEER population data analysis.","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"issue":"31","key":"doi230035r5","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal.","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"doi230035r6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jid.2019.07.712","article-title":"Overall survival in mycosis fungoides: a systematic review and meta-analysis.","volume":"140","author":"Mourad","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"32","key":"doi230035r7","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model.","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"doi230035r8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi230035r9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jdermsci.2009.10.010","article-title":"Prognosis of 100 Japanese patients with mycosis fungoides and S\u00e9zary syndrome.","volume":"57","author":"Suzuki","year":"2010","journal-title":"J Dermatol Sci"},{"issue":"3","key":"doi230035r10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jdermsci.2013.04.020","article-title":"Prognostic factors in 105 Japanese cases of mycosis fungoides and S\u00e9zary syndrome: clusterin expression as a novel prognostic factor.","volume":"71","author":"Tobisawa","year":"2013","journal-title":"J Dermatol Sci"},{"issue":"6","key":"doi230035r11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jaad.2021.06.860","article-title":"Clinical characteristics and long-term outcome of 223 patients with mycosis fungoides at a single tertiary center in Korea: a 29-year review.","volume":"86","author":"Suh","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi230035r12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/jdv.2019.33.issue-8","article-title":"Epidemiology and prognostic factors for mycosis fungoides and S\u00e9zary syndrome in a multi-ethnic Asian cohort: a 12-year review.","volume":"33","author":"Lim","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi230035r13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/bjd.2019.180.issue-5","article-title":"Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease.","volume":"180","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi230035r14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jaad.2017.04.1137","article-title":"Racial disparity in mycosis fungoides: an analysis of 4495 cases from the US National Cancer Database.","volume":"77","author":"Su","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi230035r15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jaad.2008.09.063","article-title":"Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides.","volume":"60","author":"Sun","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"doi230035r16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"2","key":"doi230035r17","first-page":"265","article-title":"Transformation of cutaneous T cell lymphoma to large cell lymphoma: a clinicopathologic and immunologic study.","volume":"132","author":"Salhany","year":"1988","journal-title":"Am J Pathol"},{"issue":"7","key":"doi230035r18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"issue":"12","key":"doi230035r19","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides.","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"18","key":"doi230035r20","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009.","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"doi230035r21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jaad.2013.09.007","article-title":"Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.","volume":"70","author":"Kadin","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi230035r22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"2","key":"doi230035r23","doi-asserted-by":"publisher","first-page":"223.e1","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): part II--prognosis, management, and future directions.","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi230035r24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaad.2014.10.019","article-title":"Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and S\u00e9zary syndrome in the southeastern United States: a single-institution cohort.","volume":"72","author":"Desai","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi230035r25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/ijd.v61.4","article-title":"Characteristics and outcomes of 727 patients with mycosis fungoides and S\u00e9zary syndrome from a Brazilian cohort.","volume":"61","author":"Miyashiro","year":"2022","journal-title":"Int J Dermatol"},{"issue":"5","key":"doi230035r26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/bjd.15000","article-title":"Prognostic indicators for mycosis fungoides in a Greek population.","volume":"176","author":"Nikolaou","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230035r27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5021\/ad.2020.32.1.14","article-title":"Mycosis fungoides and variants of mycosis fungoides: a retrospective study of 93 patients in a chinese population at a single center.","volume":"32","author":"Luo","year":"2020","journal-title":"Ann Dermatol"},{"issue":"6","key":"doi230035r28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/bjd.v181.6","article-title":"Clinical characteristics of primary cutaneous lymphoma: analysis from two centres in China.","volume":"181","author":"Shi","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi230035r29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ijd.2005.44.issue-3","article-title":"Mycosis fungoides: a retrospective study of 40 cases in Hong Kong.","volume":"44","author":"Ku","year":"2005","journal-title":"Int J Dermatol"},{"issue":"7","key":"doi230035r30","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.pathol.2018.08.008","article-title":"Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression.","volume":"50","author":"Wang","year":"2018","journal-title":"Pathology"},{"key":"doi230035r31","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4057661","article-title":"Primary cutaneous lymphomas in Thailand: a 10-year retrospective study.","volume":"2021","author":"Pruksaeakanan","year":"2021","journal-title":"Biomed Res Int"},{"issue":"2","key":"doi230035r32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.2019.181.issue-2","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi230035r33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020.","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"doi230035r34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjd.2019.180.issue-3","article-title":"British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"doi230035r35","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"doi230035r36","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"doi230035r37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jaad.2021.01.026","article-title":"Gender differences in clinical presentation, treatment, and outcomes in mycosis fungoides.","volume":"86","author":"Behbahani","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2808641\/jamadermatology_chen_2023_oi_230035_1697555529.72769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T11:09:19Z","timestamp":1697627359000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2808641"}},"subtitle":["A 12-Year Review"],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.2634","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}